Skip to main content
. 2021 Sep 25;145:112243. doi: 10.1016/j.biopha.2021.112243

Fig. 2.

Fig. 2

A. Fasting blood glucose levels at baseline (Day 0), day 15 and day 30 in the different treatment arms of COVID-19 subjects showing decrease in the all groups; B-D: Erythrocyte sedimentation rate (ESR) values in subjects with COVID-19 B. Gr. 1: Control (Standard treatment), C. Gr. 2: (Standard treatment + AFO-202 beta glucan supplementation); and D. Gr. 3: (Standard treatment + AFO-202 and N-163 beta glucan supplementation) at baseline (day 0), day 15 and day 30.